When was Discuva founded?

Discuva was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Discuva located?

Discuva is headquartered in Cambridge, United Kingdom.

Which legal entities is Discuva associated with?

Discuva is associated with Discuva Limited.

How many employees does Discuva have?

As of Dec 31, 2022, the latest employee count at Discuva is 10.

Is Discuva a funded company?

Discuva is a funded company, having raised a total of $5.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 02, 2011.

How much is Discuva worth?

The last known valuation of Discuva was £***** as of Dec 20, 2012.

When was the latest funding round of Discuva?

Discuva's latest funding was a $***** Seed round on Dec 20, 2012, with participation from 0 investor. Its primary sector is Infectious Diseases. Globally, the Infectious Diseases sector has seen $341M in funding in 2026 to date.

What is the annual revenue of Discuva?

Annual revenue of Discuva is between £1M and £10M as on Jan 31, 2018

Where does Discuva rank among its competitors?

Discuva ranks 48th amongst 201 active competitors, of which 76 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Discuva?

Discuva's top competitors include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma. Among them, Vedanta Biosciences secured the most recent funding round in February, 2024.

Discuva - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Discuva an acquired company?

Discuva got acquired by Summit on Dec 23, 2017.

Company Details

Developer of antimicrobials against drug-resistant bacterial pathogens. Its proprietary platform technologies collectively called SATIN (Selective Antibiotic Target IdentificatioN) comprises of several different varieties of transposon library which have been engineered for each target pathogen. Using this platform, it has developed its pipeline with its initial focus on providing therapeutics for major hospital and community-based infections.

Website: discuva.com
Social
Email ID: *****@discuva.com
Part Of

Key Metrics

Founded Year

2011

Location

Cambridge, United Kingdom

Stage

Acquired

Total Funding

$5.2M in 2 rounds

Latest Funding Round

Seed, Dec 20, 2012, $*****

Last Known Valuation

£***** as on Dec 20, 2012

Investors

New Wave Ventures

Ranked

48^th among 201 active competitors

Annual Revenue

£1M - £10M as on Jan 31, 2018

Employee Count

10 as on Dec 31, 2022

Similar Companies

Spero Therapeutics & 253 more

Exit Details

Acquired by Summit (Dec 23, 2017)

View Discuva's full profile

Discuva is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Discuva Limited CIN: 6169490 , Germany, Active	Mar 18, 2007	$1M - $10M (As on Jan 31, 2018)	10 (As on Dec 31, 2022)

Discuva got acquired by Summit on Dec 23, 2017 at an acquisition amount of $*****.

Click here to take a look at Discuva's acquisition in detail

Discuva has raised a total funding of $5.2M over 2 rounds. Its first funding round was on Dec 02, 2011. Discuva has 1 institutional investor.

Here is the list of recent funding rounds of Discuva:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2012	4835113	Seed	9535597	1570576	4985616	3547929
Dec 02, 2011	5605590	Seed	6775441	2495692	8971470	New Wave Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Discuva's funding rounds and investors

The founders of Discuva are John Wain, David Williams and Clive Mason.

Here are the details of Discuva's key team members:

John Wain: Co-Founder of Discuva.
David Williams: Co-Founder of Discuva.
Clive Mason: Co-Founder of Discuva.

Discuva's Board of Directors

Discuva's board has 3 active members. Ankur Dhingra, Manmeet Singh and Robert Duggan are independent board members.

Here is the list of Discuva's board of directors:

Name	Type	Representing	Status	Duration
Ankur Dhingra	Independent board member	-	Current	3y 6m
qlij{wl	Independent board member	-	Current	2y 3m
zcszbxs	Independent board member	-	Current	1y 1m

View details of Discuva's Founder profiles and Board Members

Discuva's employee count trend

Discuva has 10 employees as of Dec 22. The total employee count is 9.0% lower than what it was in Dec 21. Here is Discuva's employee count trend over the years:

Uncover Discuva's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Discuva include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma. Here is the list of Top 10 competitors of Discuva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Partners Health Care Innovation, Atlas Venture ... & 16 others	72/100
2nd	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$350M	Invesco, Seventure Partners & 38 others	65/100
3rd	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Aisling Capital, Phase4 Partners & 23 others	64/100
4th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	62/100
5th	Aelin Therapeutics 2017, Leuven (Belgium), Series A	Developer of antibiotics based on protein aggregation approach	$31.8M	Life Sciences Partners, Boehringer Ingelheim Venture Fund ... & 5 others	61/100
6th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Janchor Partners & 12 others	61/100
7th	Cubist Pharmaceuticals 1993, Lexington (United States), Acquired	Developing drugs to treat a range of acute care related diseases	-	Vivo Capital, Cardinal Partners & 2 others	61/100
8th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	60/100
9th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Viking Global Investors, Artis Ventures & 13 others	60/100
10th	ABAC Therapeutics 2014, Barcelona (Spain), Acquired	Early stage biopharma developing precision drugs for MDR bacterial infections	$19.8M	Pontifax, Global Health Investment Fund & 7 others	60/100
48th	Discuva 2011, Cambridge (United Kingdom), Acquired	Developer of antimicrobials against drug-resistant bacterial pathogens	$5.2M	New Wave Ventures	44/100